Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость

Haas R. H., et al. Low platelet mitochondrial complex I and complex II/ III activity in early untreated Parkinson’s disease. Ann Neurol. 1995 Jun; 37(6):714–22. doi:10.1002/ana.410370604.

Henchcliffe C., Beal M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008 Nov; 4(11):600–9. doi:10.1038/ncpneuro0924.

Hosamani R., Muralidhara. Acute exposure of Drosophila melanogaster to paraquat causes oxidative stress and mitochondrial dysfunction. Arch Insect Biochem Physiol. 2013 May; 83(1):25–40. Epub 2013 Apr 5.

Isobe C., Abe T., Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2’-deoxyguanosine in the cerebrospinal fluid of patients living with Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett. 2010 Jan 18; 469(1):159–63. Epub 2009 Nov 26. Lehmann S., Martins L. M. Insights into mitochondrial quality control pathways and Parkinson’s disease. J Mol Med (Berl). 2013 Jun; 91(6):665– 71. Epub May 4. doi:10.1007/s00109-013-1044-y.

Li D. W., et al. α-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med. 2013 Jul;32(1):108–14. Epub Apr 24. doi:10.3892/ ijmm.2013.1361.

Lin T. K., et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Med J. 2009 Nov — Dec; 32(6):589–99.

Lodi R., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001 May 1; 49(5):590–6. doi:10.1002 /ana.1001.

Mena M. A., et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord. 1992; 7(1):23–31. doi:10.1002/mds.870070105.

Mizuno Y., et al. Role of mitochondria in the etiology and pathogenesis of Parkinson’s disease. Biochima et Biophysica Acta. 1995 May 24; 1271(1):265–74. doi:10.1016/0925-4439 (95)00038-6.

Mizuno Y., et al. Mitochondrial dysfunction in Parkinson’s disease. Ann Neurol. 1998 Sep; 44 (3 Suppl 1):S. 99–S. 109.

Musumeci O., et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001 Apr 10; 56(7):849–55.

Nakamura K. α-Synuclein and mitochondria: partners in crime? Neurotherapeutics. 2013 Jul; 10(3):391–9. Epub Mar 20. doi:10.1007/s13311-013-0182-9.

Olanow C. W., et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol. Nov 1995; 38(5):771–7. doi:10.1002/ ana.410380512.

Perfeito R., Cunha-Oliveira T., Rego A. C. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease — resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 2012 Nov 1; 53(9):1791–806. doi:10.1016/j.freerad-biomed.2012.08.569.

Przedborski S., Jackson-Lewis V., Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord. May 1995; 10(3):312–7. doi:10.1002/mds.870100314.

Schapira A. H., et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat Rev Drug Discov. 2006 Oct; 5(10):845–54. doi:10.1038/nrd2087.

Shults C. W., et al. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early Parkinsonism. Neurol. 1995 Feb; 45(2):344–8. doi:10.1212/WNL.45.2.344.

Shults C. W., et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonpar-kinsonian subjects. Ann Neurol. 1997 Aug. 42(2):261–4. doi:10.1002/ ana.410420221.

Shults C. W., et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998 Mar; 50(3):793–5. doi:10.1212 /WNL.50.3.793.

Shults C. W., Haas R. H., Beal M. F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors. 1999; 9(2–4):267–72. doi:10.1002/biof.5520090223.

Smith T. S., Parker W. D., Bennell J. P. Jr. L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreportl. 1994 Apr 14; 5(8):1009–11. doi:10.1097/00001756-199404000-00039.

Subramaniam S. R., Chesselet M. F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013 Jul — Aug;